山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (10): 80-85.doi: 10.6040/j.issn.1671-7554.0.2019.104
朱爱国,马振敕,王健
ZHU Aiguo, MA Zhenchi, WANG Jian
摘要: 目的 通过基因表达谱汇编(GEO)数据库和癌症基因组图谱(TCGA)数据库筛选并建立与上皮源性卵巢癌(EOC)患者预后有关联的多基因模型,并验证其预后价值。 方法 从GEO数据库中下载EOC有关芯片数据(GSE14407),筛选出在EOC组织和正常卵巢上皮组织中差异表达的基因(DEGs),采用单因素和多因素Cox回归模型筛选出与预后有关联的DEGs,建立多基因预后模型和预后指数(PI)公式。对TCGA数据库中EOC患者的mRNA数据及临床信息进行整理,通过PI公式对患者进行评分,并根据评分将患者分为低风险组和高风险组。通过Cox回归风险模型分析临床病理参数(年龄、发病位置、组织分级、肿瘤残余及FIGO分期)和预后指数参数与EOC预后的关系。根据年龄、发病位置、组织分级、肿瘤残余及FIGO分期进行分组,采用Kaplan-Meier(K-M)生存分析验证多基因模型对卵巢癌的预后价值。 结果 共筛选出47个在EOC组织和正常卵巢组织中的DEGs,其中有37个表达下调的DEGs和10个表达上调的DEGs。将上述DEGs进行单因素和多因素Cox回归分析,共筛选出4个DEGs,分别是PACSIN3、KCNT1、LAMP3及KIR3DX1。PI公式:(-0.169×PACSIN3的表达量+0.078×KCNT1的表达量-0.246×LAMP3的表达量-0.147×KIR3DX1的表达量)。Cox回归模型分析证实,年龄、肿瘤残余和预后模型是卵巢癌患者的独立预后因素(P<0.01)。通过K-M生存分析证实,在TCGA数据库的312例EOC患者中,预后评分低风险的患者总体生存期(OS)较高风险患者延长,差异有统计学意义(P<0.05)。在不同的年龄、临床分期、发病位置(单侧和双侧)、肿瘤残余<10 mm的EOC患者亚组中,预后评分低风险的患者OS较高风险患者延长,差异有统计学意义(P<0.05)。 结论 四基因预后模型是EOC患者的独立预后因素,并在总体和根据各临床病理特征分组的EOC患者亚组中得到了验证。
中图分类号:
| [1] 陈静, 李春艳, 赵苗青, 等. EZH2蛋白在卵巢上皮性肿瘤中的表达及其作用[J]. 山东大学学报(医学版), 2015, 53(2): 65-70. CHEN Jing, LI Chunyan, ZHAO Miaoqing, et al. Expression of EZH2 protein and its role in ovarian epithelial tumor [J]. Journal of Shandong University(Health Sciences), 2015, 53(2): 65-70. [2] Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise[J]. Gynecol Oncol, 2014, 133(2): 362-369. [3] Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(suppl_8): viii61-viii65. [4] Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer[J]. Oncology(Williston Park), 2016, 30(2): 166-176. [5] 邱建,傅云峰,周彩云,等. 上皮性卵巢癌组织CK2β和p53蛋白表达临床意义分析[J].中华肿瘤防治杂志, 2015,22(6): 451-456. QIU Jian, FU Yunfeng, ZHOU Caiyun, et al. Analysis of the relationship between expression of CK2β, p53 and prognosis in epithelial ovarian cancer tissues[J]. Chin J Cancer Prev Treat, 2015, 22(6): 451-456. [6] Nakonechny QB, Gilks CB. Ovarian cancer in hereditary cancer susceptibility syndromes[J]. Surg Pathol Clin, 2016, 9(2): 189-199. [7] Zhang M, Zhuang G, Sun X, et al. TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer[J]. Diagn Pathol, 2017, 12(1):16. doi: 10.1186/s13000-017-0605-8. [8] Darcy KM, Brady WE, Mcbroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008, 111(3): 487-495. [9] Seagle BLL, Yang CPH, Eng KH, et al. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas[J]. Gynecol Oncol, 2015, 138(1): 159-164. [10] Kotsopoulos J, Rosen B, Fan I, et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status[J]. Gynecol Oncol, 2016, 140(1): 42-47. [11] Arts-de Jong M, de Bock GH, van Asperen CJ, et al. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review[J]. Eur J Cancer, 2016, 61:137-145. doi: 10.1016/j.ejca.2016.03.009. [12] Dumas J, Gargano MA, Dancik GM. shinyGEO: a web-based application for analyzing Gene Expression Omnibus datasets[J]. Bioinformatics, 2016, 32(23): 3679-3681. [13] Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data[J]. Nucleic Acids Res, 2016, 44(8): e71. doi: 10.1093/nar/gkv1507. [14] Zhou W, Ma C, Yan Z. Microarray data analysis reveals differentially expressed genes in prolactinoma[J]. Neoplasma, 2015, 62(1): 53-60. [15] 毛燕南, 曾丽霞, 李宇虹, 等. PAX8、PAX2、p53和RAS蛋白在卵巢及输卵管组织中的表达对于高级别卵巢浆液性癌起源的意义[J]. 中华妇产科杂志, 2017, 52(10): 687-696. MAO Yannan, ZENG Lixia, LI Yuhong, et al. Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma[J]. Zhonghua Fu Chan Ke Za Zhi, 2017, 52(10): 687-696. [16] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 4: 3-14. doi: 10.1016/j.bpobgyn.2016.08.006. [17] Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 4: 31-48. doi: 10.1016/j.bpobgyn.2016.10.017. [18] Graffeo R, Livraghi L, Pagani O, et al. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care[J]. Breast Cancer Res Tr, 2016, 160(3): 393-410. [19] Schael S, Nuchel J, Muller S, et al. Casein kinase 2 phosphorylation of protein kinase C and casein kinase 2 substrate in neurons(PACSIN)1 protein regulates neuronal spine formation[J]. J Biol Chem, 2013, 288(13): 9303-9312. [20] Roach W, Plomann M. PACSIN3 overexpression increases adipocyte glucose transport through GLUT1[J]. Biochem Biophys Res Commun, 2007, 355(3): 745-750. [21] Lim CX, Ricos MG, Dibbens LM, et al. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects[J]. J Med Genet, 2016, 53(4): 217-225. [22] Rizzo F, Ambrosino P, Guacci A, et al. Characterization of two De novo Kcnt1 mutations in children with malignant migrating partial seizures in infancy[J]. Mol Cell Neurosci, 2016, 72: 54-63. doi: 10.1016/j.mcn.2016.01.004. [23] Nagelkerke A, Sieuwerts AM, Bussink J, et al. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy[J]. Endocr Relat Cancer, 2013, 21(1): 101-112. [24] Liao X, Chen Y, Liu D, et al. High expression of LAMP3 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma[J]. Int J Mol Sci, 2015, 16(8): 17655-17667. [25] Qiu X, You Y, Huang J, et al. LAMP3 and TP53 overexpression predicts poor outcome in laryngeal squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(5): 5519-5527. |
| [1] | 张秋萍,朱慧志,吕川,夏咏琪,张秀. 基于生物信息学分析鉴定哮喘潜在的关键自噬和铁死亡相关基因[J]. 山东大学学报 (医学版), 2026, 64(1): 74-87. |
| [2] | 李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115. |
| [3] | 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74. |
| [4] | 王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54. |
| [5] | 贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99. |
| [6] | 杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110. |
| [7] | 杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121. |
| [8] | 刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35. |
| [9] | 陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71. |
| [10] | 袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107. |
| [11] | 王静,刘晓菲,曾荣,许长娟,张锦涛,董亮. 基于机器学习算法鉴定哮喘的坏死性凋亡相关生物标志物[J]. 山东大学学报 (医学版), 2024, 62(7): 21-32. |
| [12] | 郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16. |
| [13] | 魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94. |
| [14] | 刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30. |
| [15] | 杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69. |
|
||